Neuland Laboratories (524558) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 revenue declined 32.4% year-over-year to ₹316 crores, mainly due to uneven order flow and subdued specialty GDS business; performance was below expectations, but management remains confident in achieving FY26 growth targets as new capacities and commercial molecules ramp up.

• EBITDA for the quarter was ₹42.1 crores with a margin of 14.4%; profit after tax was ₹13.7 crores, and EPS stood at ₹10.7.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, were approved by the Board on July 31, 2025.

• Dr. Ravi Shankar Gopinath appointed as an Additional Independent Director for five years, effective August 1, 2025, pending shareholder approval.

• Management continues to invest in talent, capabilities, and cost optimization to strengthen CDMO positioning.

Financial highlights

• Q1 FY26 revenue was ₹316 crores (consolidated: ₹29,275.27 lakhs), down 32.4% year-over-year; total income at ₹30,060.86 lakhs.

• EBITDA for Q1FY26 was ₹42.1 crores, a 67.2% decline year-over-year, with EBITDA margin at 14.4%.

• PAT for Q1FY26 was ₹13.7 crores, down 86.1% year-over-year; EPS at ₹10.7.

• Working capital increased to 145 days of sales due to higher inventory; free cash flow was negative ₹66 crores.

• Net debt stood at negative ₹165 crores at Q1FY26 end, reflecting a strong balance sheet.

Outlook and guidance

• Management expects healthy growth for FY26, driven by investments, new capacities, and a robust pipeline of commercial molecules and projects.

• Revenue growth is expected to resume on the FY24 base, with a 20% CAGR over 3–5 years.

• Margins are expected to recover as sales ramp up, though no specific EBITDA margin guidance was provided.

• Commercialization of a new CMS molecule and the Unit 3 production block are key milestones for the year.